Jared R. Brosch, MD | IU Health

Dr. Jared Brosch

Claim this profile

Indiana University School of Medicine

Studies Alzheimer's Disease
Studies Dementia
11 reported clinical trials
20 drugs studied

Area of expertise

1

Alzheimer's Disease

Jared Brosch has run 10 trials for Alzheimer's Disease. Some of their research focus areas include:

APP positive
PSEN1 positive
PSEN2 positive
2

Dementia

Jared Brosch has run 9 trials for Dementia. Some of their research focus areas include:

APP positive
PSEN1 positive
PSEN2 positive

Affiliated Hospitals

Image of trial facility.

Indiana University School Of Medicine

Image of trial facility.

Indiana University Health Neuroscience Center

Clinical Trials Jared Brosch is currently running

Image of trial facility.

Gantenerumab

for Alzheimer's Disease

The purpose is to evaluate the biomarker effect, safety, and tolerability of investigational study drugs in participants who are known to have an Alzheimer's disease (AD)-causing mutation. Stage 1 will determine if treatment with the study drug prevents or slows the rate of amyloid beta (Aβ) pathological disease accumulation demonstrated by Aβ positron emission tomography (PET) imaging. Stage 2 will evaluate the effect of early Aβ plaque reduction/prevention on disease progression by assessing downstream non-Aβ biomarkers of AD (e.g., CSF total tau, p-tau, NfL) compared to an external control group from the DIAN-OBS natural history study and the DIAN-TU-001 placebo-treated participants.

Recruiting

0 awards

Phase 2 & 3

10 criteria

Image of trial facility.

Remternetug

for Alzheimer's Disease

The purpose of this research study is to test the study drug, referred to as remternetug, to determine its effectiveness for the study treatment of asymptomatic (at risk) Alzheimer disease in individuals with AD-causing mutations. This study will also investigate the effects of remternetug on biomarkers (measures of the disease including brain scans, blood and spinal fluid tests), examine safety data to identify any potential benefits or risks, and examine how well participants can tolerate remternetug. Stage 1 will determine if treatment with the study drug prevents or reverses amyloid beta (Aβ) accumulation compared with placebo in participants with dominantly inherited Alzheimer's disease (DIAD). Stage 2 will evaluate the effect of early anti-amyloid treatment on downstream biomarkers of AD in treated participants compared to external control groups.

Recruiting

0 awards

Phase 2 & 3

2 criteria

More about Jared Brosch

Clinical Trial Related

5 years of experience running clinical trials · Led 11 trials as a Principal Investigator · 4 Active Clinical Trials

Treatments Jared Brosch has experience with

  • Donanemab
  • Lecanemab
  • Gantenerumab
  • E2814
  • Extended Release Niacin
  • Solanezumab

Other Doctors you might be interested in

Frequently asked questions

Do I need insurance to participate in a trial?

What does Jared Brosch specialize in?

Is Jared Brosch currently recruiting for clinical trials?

Are there any treatments that Jared Brosch has studied deeply?

What is the best way to schedule an appointment with Jared Brosch?

What is the office address of Jared Brosch?

Is there any support for travel costs?

Unbiased Results

We believe in providing patients with all the options.

Your Data Stays Your Data

We only share your information with the clinical trials you're trying to access.

Verified Trials Only

All of our trials are run by licensed doctors, researchers, and healthcare companies.

Terms of Service·Privacy Policy·Cookies·Security